Peptide fragments of bradykinin show unexpected biological activity not mediated by B
Journal
British journal of pharmacology
ISSN: 1476-5381
Titre abrégé: Br J Pharmacol
Pays: England
ID NLM: 7502536
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
revised:
02
12
2021
received:
24
01
2021
accepted:
22
12
2021
pubmed:
4
1
2022
medline:
18
5
2022
entrez:
3
1
2022
Statut:
ppublish
Résumé
Bradykinin (BK-(1-9)) is an endogenous nonapeptide involved in multiple physiological and pathological processes. Peptide fragments of bradykinin are believed to be biologically inactive. We have now tested the two major peptide fragments of bradykinin in human and animals. BK peptides were quantified by MS in male rats. NO release was quantified from human, mouse and rat cells loaded with DAF-FM. Rat aortic rings were used to measure vascular reactivity. Changes in BP and HR were measured in conscious male rats. To evaluate pro-inflammatory effects both vascular permeability and nociception were measured in adult mice. BK-(1-7) and BK-(1-5) are produced in vivo from BK-(1-9). Both peptides induced NO production in all cell types tested. However, unlike BK-(1-9), NO production elicited by BK-(1-7) or BK-(1-5) was not inhibited by B BK-(1-7) and BK-(1-5) are endogenous peptides present in plasma. BK-related peptide fragments show biological activity, not mediated by B
Sections du résumé
BACKGROUND AND PURPOSE
Bradykinin (BK-(1-9)) is an endogenous nonapeptide involved in multiple physiological and pathological processes. Peptide fragments of bradykinin are believed to be biologically inactive. We have now tested the two major peptide fragments of bradykinin in human and animals.
EXPERIMENTAL APPROACH
BK peptides were quantified by MS in male rats. NO release was quantified from human, mouse and rat cells loaded with DAF-FM. Rat aortic rings were used to measure vascular reactivity. Changes in BP and HR were measured in conscious male rats. To evaluate pro-inflammatory effects both vascular permeability and nociception were measured in adult mice.
KEY RESULTS
BK-(1-7) and BK-(1-5) are produced in vivo from BK-(1-9). Both peptides induced NO production in all cell types tested. However, unlike BK-(1-9), NO production elicited by BK-(1-7) or BK-(1-5) was not inhibited by B
CONCLUSIONS AND IMPLICATIONS
BK-(1-7) and BK-(1-5) are endogenous peptides present in plasma. BK-related peptide fragments show biological activity, not mediated by B
Substances chimiques
Peptide Fragments
0
Receptor, Bradykinin B1
0
Receptor, Bradykinin B2
0
Receptors, Bradykinin
0
Bradykinin
S8TIM42R2W
Banques de données
figshare
['10.6084/m9.figshare.17100302']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3061-3077Informations de copyright
© 2022 The British Pharmacological Society.
Références
Ahmad, M., Zeitlin, I. J., Parratt, J. R., & Pitt, A. R. (2006). Degradation of bradykinin, a cardioprotective substance, during a single passage through isolated rat-heart. Archives of Pharmacal Research, 29, 241-248. https://doi.org/10.1007/BF02969400
Alexander, S. P., Christopoulos, A., Davenport, A. P., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Southan, C., Davies, J. A., Abbracchio, M. P., Alexander, W., Al-hosaini, K., Bäck, M., Barnes, N. M., Bathgate, R., … Ye, R. D. (2021). THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors. British Journal of Pharmacology, 178(S1), S27-S156. https://doi.org/10.1111/bph.15538
Amaral, F. A., Bastos, L. F., Oliveira, T. H., Dias, A. C., Oliveira, V. L., Tavares, L. D., Costa, V. V., Galvão, I., Soriani, F. M., Szymkowski, D. E., & Ryffel, B. (2016). Transmembrane TNF-alpha is sufficient for articular inflammation and hypernociception in a mouse model of gout. European Journal of Immunology, 46, 204-211. https://doi.org/10.1002/eji.201545798
Bakhle, Y. S. (1968). Conversion of angiotensin I to angiotensin II by cell-free extracts of dog lung. Nature, 220, 919-921. https://doi.org/10.1038/220919a0
Bastian S., Loillier B., Paquet J. L., & Pruneau D. (1997). Stable expression of human kinin B1receptor in 293 cells: pharmacological and functional characterization. British Journal of Pharmacology, 122(2), 393-399. https://doi.org/10.1038/sj.bjp.0701380
Blais, C. Jr., Marceau, F., Rouleau, J. L., & Adam, A. (2000). The kallikrein-kininogen-kinin system: Lessons from the quantification of endogenous kinins. Peptides, 21, 1903-1940. https://doi.org/10.1016/S0196-9781(00)00348-X
Campbell, D. J. (2013). Bradykinin peptides. In A. J. Kastin (Ed.), Handbook of biologically active peptides (2nd ed.) (pp. 1386-1393).
Cayla, C., Labuz, D., Machelska, H., Bader, M., Schafer, M., & Stein, C. (2012). Impaired nociception and peripheral opioid antinociception in mice lacking both kinin B1 and B2 receptors. Anesthesiology, 116, 448-457. https://doi.org/10.1097/ALN.0b013e318242b2ea
Chan, W. C., & White, P. D. (2000). Fmoc solid phase peptide synthesis-A practical approach. Oxford University Press.
Cicardi, M., Banerji, A., Bracho, F., Malbran, A., Rosenkranz, B., Riedl, M., Bork, K., Lumry, W., Aberer, W., Bier, H., & Bas, M. (2010). Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. The New England Journal of Medicine, 363, 532-541. https://doi.org/10.1056/NEJMoa0906393
Curtis, M. J., Alexander, S., Cirino, G., Docherty, J. R., George, C. H., Giembycz, M. A., Hoyer, D., Insel, P. A., Izzo, A. A., Ji, Y., MacEwan, D. J., Sobey, C. G., Stanford, S. C., Teixeira, M. M., Wonnacott, S., & Ahluwalia, A. (2018). Experimental design and analysis and their reporting II: Updated and simplified guidance for authors and peer reviewers. British Journal of Pharmacology, 175, 987-993. https://doi.org/10.1111/bph.14153
Elliott, D. F., Horton, E. W., & Lewis, G. P. (1960). Actions of pure bradykinin. The Journal of Physiology, 153, 473-480. https://doi.org/10.1113/jphysiol.1960.sp006548
Ferreira, S. H., Greene, L. H., Alabaster, V. A., Bakhle, Y. S., & Vane, J. R. (1970). Activity of various fractions of bradykinin potentiating factor against angiotensin I converting enzyme. Nature, 225, 379-380. https://doi.org/10.1038/225379a0
Ferreira, S. H., & Vane, J. R. (1967). The disappearance of bradykinin and eledoisin in the circulation and vascular beds of the cat. British Journal of Pharmacology and Chemotherapy, 30, 417-424. https://doi.org/10.1111/j.1476-5381.1967.tb02148.x
Garvin, M. R., Alvarez, C., Miller, J. I., Prates, E. T., Walker, A. M., Amos, B. K., Mast, A. E., Justice, A., Aronow, B., & Jacobson, D. (2020). A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. eLife, 9, e59177.
Gomes, E. R., Lara, A. A., Almeida, P. W., Guimaraes, D., Resende, R. R., Campagnole-Santos, M. J., Bader, M., Santos, R. A., & Guatimosim, S. (2010). Angiotensin-(1-7) prevents cardiomyocyte pathological remodeling through a nitric oxide/guanosine 3′,5′-cyclic monophosphate-dependent pathway. Hypertension, 55, 153-160. https://doi.org/10.1161/HYPERTENSIONAHA.109.143255
Guatimosim, S., Amaya, M. J., Guerra, M. T., Aguiar, C. J., Goes, A. M., Gomez-Viquez, N. L., Rodrigues, M. A., Gomes, D. A., Martins-Cruz, J., Lederer, W. J., & Leite, M. F. (2008). Nuclear Ca2+ regulates cardiomyocyte function. Cell Calcium, 44, 230-242. https://doi.org/10.1016/j.ceca.2007.11.016
Guyenet, P. G. (2006). The sympathetic control of blood pressure. Nature Reviews. Neuroscience, 7, 335-346. https://doi.org/10.1038/nrn1902
Habal, F. M., & Movat, H. Z. (1976). Kininogens of human plasma. Seminars in Thrombosis and Hemostasis, 3, 27-42.
Heusch, G., Botker, H. E., Przyklenk, K., Redington, A., & Yellon, D. (2015). Remote ischemic conditioning. Journal of the American College of Cardiology, 65, 177-195. https://doi.org/10.1016/j.jacc.2014.10.031
Jesus, I. C. G., Scalzo, S., Alves, F., Marques, K., Rocha-Resende, C., Bader, M., Santos, R. A., & Guatimosim, S. (2018). Alamandine acts via MrgD to induce AMPK/NO activation against ANG II hypertrophy in cardiomyocytes. American Journal of Physiology. Cell Physiology, 314, C702-C711. https://doi.org/10.1152/ajpcell.00153.2017
Kang, D. S., Ryberg, K., Morgelin, M., & Leeb-Lundberg, L. M. (2004). Spontaneous formation of a proteolytic B1 and B2 bradykinin receptor complex with enhanced signaling capacity. The Journal of Biological Chemistry, 279, 22102-22107. https://doi.org/10.1074/jbc.M402572200
Kempe, S., Fois, G., Brunner, C., Hoffmann, T. K., Hahn, J., & Greve, J. (2020). Bradykinin signaling regulates solute permeability and cellular junction organization in lymphatic endothelial cells. Microcirculation, 27, e12592.
Kopylov, A. T., Myasoedov, N. F., Dadayan, A. K., Zgoda, V. G., Medvedev, A. E., & Zolotarev, Y. A. (2016). Use of deuterium labeling by high-temperature solid-state hydrogen-exchange reaction for mass spectrometric analysis of bradykinin biotransformation. Rapid Communications in Mass Spectrometry: RCM, 30, 1283-1294. https://doi.org/10.1002/rcm.7558
Leeb-Lundberg, L. M., Marceau, F., Muller-Esterl, W., Pettibone, D. J., & Zuraw, B. L. (2005). International union of pharmacology. XLV. Classification of the kinin receptor family: From molecular mechanisms to pathophysiological consequences. Pharmacological Reviews, 57, 27-77. https://doi.org/10.1124/pr.57.1.2
Lilley, E., Stanford, S. C., Kendall, D. E., Alexander, S. P. H., Cirino, G., Docherty, J. R., George, C. H., Insel, P. A., Izzo, A. A., Ji, Y., Panettieri, R. A., Sobey, C. G., Stefanska, B., Stephens, G., Teixeira, M., & Ahluwalia, A. (2020). ARRIVE 2.0 and the British Journal of Pharmacology: Updated guidance for 2020. British Journal of Pharmacology, 177, 3611-3616. https://doi.org/10.1111/bph.15178
Livak, K. J., & Schmittgen, T. D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods, 25, 402-408. https://doi.org/10.1006/meth.2001.1262
Marceau, F., Bachelard, H., Bouthillier, J., Fortin, J. P., Morissette, G., Bawolak, M. T., Charest-Morin, X., & Gera, L. (2020). Bradykinin receptors: Agonists, antagonists, expression, signaling, and adaptation to sustained stimulation. International Immunopharmacology, 82, 106305. https://doi.org/10.1016/j.intimp.2020.106305
Marshall, P., Heudi, O., McKeown, S., Amour, A., & Abou-Shakra, F. (2002). Study of bradykinin metabolism in human and rat plasma by liquid chromatography with inductively coupled plasma mass spectrometry and orthogonal acceleration time-of-flight mass spectrometry. Rapid Communications in Mass Spectrometry: RCM, 16, 220-228. https://doi.org/10.1002/rcm.565
McEachern, A. E., Shelton, E. R., Bhakta, S., Obernolte, R., Bach, C., Zuppan, P., Fujisaki, J., Aldrich, R. W., & Jarnagin, K. (1991). Expression cloning of a rat B2 bradykinin receptor. Proceedings of the National Academy of Sciences of the United States of America, 88, 7724-7728. https://doi.org/10.1073/pnas.88.17.7724
Menke, J. G., Borkowski, J. A., Bierilo, K. K., MacNeil, T., Derrick, A. W., Schneck, K. A., Ransom, R. W., Strader, C. D., Linemeyer, D. L., & Hess, J. F. (1994). Expression cloning of a human B1 bradykinin receptor. The Journal of Biological Chemistry, 269, 21583-21586. https://doi.org/10.1016/S0021-9258(17)31844-6
Murphey, L. J., Hachey, D. L., Oates, J. A., Morrow, J. D., & Brown, N. J. (2000). Metabolism of bradykinin in vivo in humans: Identification of BK1-5 as a stable plasma peptide metabolite. The Journal of Pharmacology and Experimental Therapeutics, 294, 263-269.
Oldenburg, O., Qin, Q., Krieg, T., Yang, X. M., Philipp, S., Critz, S. D., Cohen, M. V., & Downey, J. M. (2004). Bradykinin induces mitochondrial ROS generation via NO, cGMP, PKG, and mitoKATP channel opening and leads to cardioprotection. American Journal of Physiology. Heart and Circulatory Physiology, 286, H468-H476. https://doi.org/10.1152/ajpheart.00360.2003
Orfanos, S. E., Langleben, D., Khoury, J., Schlesinger, R. D., Dragatakis, L., Roussos, C., Ryan, J. W., & Catravas, J. D. (1999). Pulmonary capillary endothelium-bound angiotensin-converting enzyme activity in humans. Circulation, 99, 1593-1599. https://doi.org/10.1161/01.CIR.99.12.1593
Park, W. K., St-Pierre, S. A., Barabe, J., & Regoli, D. (1978). Synthesis of peptides by the solid-phase method. III. Bradykinin: Fragments and analogs. Canadian Journal of Biochemistry, 56, 92-100. https://doi.org/10.1139/o78-015
Percie du Sert, N., Hurst, V., Ahluwalia, A., Alam, S., Avey, M. T., Baker, M., Browne, W. J., Clark, A., Cuthill, I. C., Dirnagl, U., Emerson, M., Garner, P., Holgate, S. T., Howells, D. W., Karp, N. A., Lazic, S. E., Lidster, K., MacCallum, C. J., Macleod, M., … Würbel, H. (2020). The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biology, 18(7), e3000410. https://doi.org/10.1371/journal.pbio.3000410
Ramirez-Molina, C., Heudi, O., Pullen, M., & Marshall, P. S. (2006). Study of bradykinin metabolism by rat lung tissue membranes and rat kidney brush border membranes by HPLC with inductively coupled plasma-mass spectrometry and orthogonal acceleration time-of-flight mass spectrometry. Journal of Peptide Science: An Official Publication of the European Peptide Society, 12, 220-226. https://doi.org/10.1002/psc.712
Redman, L. W., Regoli, D., & Tustanoff, E. R. (1979). Immunological and biological activities of fragments and analogs of bradykinin. Canadian Journal of Biochemistry, 57, 529-539. https://doi.org/10.1139/o79-067
Regoli, D., Barabe, J., & Park, W. K. (1977). Receptors for bradykinin in rabbit aortae. Canadian Journal of Physiology and Pharmacology, 55, 855-867. https://doi.org/10.1139/y77-115
Regoli, D., & Gobeil, F. Jr. (2015). Critical insights into the beneficial and protective actions of the kallikrein-kinin system. Vascular Pharmacology, 64, 1-10. https://doi.org/10.1016/j.vph.2014.12.003
Regoli, D., & Gobeil, F. (2016). Kinins and peptide receptors. Biological Chemistry, 397, 297-304. https://doi.org/10.1515/hsz-2015-0240
Rocha, E. S. M., Beraldo, W. T., & Rosenfeld, G. (1949). Bradykinin, a hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin. The American Journal of Physiology, 156, 261-273.
Rocha-Resende, C., Leao, N. M., de Lima, M. E., Santos, R. A., Pimenta, A. M. C., & Verano-Braga, T. (2017). Moving pieces in a cryptomic puzzle: Cryptide from Tityus serrulatus Ts3 Nav toxin as potential agonist of muscarinic receptors. Peptides, 98, 70-77. https://doi.org/10.1016/j.peptides.2016.12.018
Rocha-Resende, C., Roy, A., Resende, R., Ladeira, M. S., Lara, A., de Morais Gomes, E. R., Prado, V. F., Gros, R., Guatimosim, C., Prado, M. A. M., & Guatimosim, S. (2012). Non-neuronal cholinergic machinery present in cardiomyocytes offsets hypertrophic signals. Journal of Molecular and Cellular Cardiology, 53, 206-216. https://doi.org/10.1016/j.yjmcc.2012.05.003
Roch-Arveiller, M., Caranikas, S., Regoli, D., & Giroud, J. P. (1983). Effects of bradykinin and some of its fragments on smooth muscles and chemotaxis. European Journal of Pharmacology, 88, 99-103. https://doi.org/10.1016/0014-2999(83)90396-5
Ryan, J. W., Berryer, P., Chung, A. Y., & Sheffy, D. H. (1994). Characterization of rat pulmonary vascular aminopeptidase P in vivo: Role in the inactivation of bradykinin. The Journal of Pharmacology and Experimental Therapeutics, 269, 941-947.
Ryan, J. W., Roblero, J., & Stewart, J. M. (1968). Inactivation of bradykinin in the pulmonary circulation. The Biochemical Journal, 110, 795-797. https://doi.org/10.1042/bj1100795
Santos, R. A. S., Oudit, G. Y., Verano-Braga, T., Canta, G., Steckelings, U. M., & Bader, M. (2019). The renin-angiotensin system: Going beyond the classical paradigms. American Journal of Physiology. Heart and Circulatory Physiology, 316, H958-H970. https://doi.org/10.1152/ajpheart.00723.2018
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012). NIH image to ImageJ: 25 years of image analysis. Nature Methods, 9, 671-675. https://doi.org/10.1038/nmeth.2089
Schoemaker, R. G., & van Heijningen, C. L. (2000). Bradykinin mediates cardiac preconditioning at a distance. American Journal of Physiology. Heart and Circulatory Physiology, 278, H1571-H1576. https://doi.org/10.1152/ajpheart.2000.278.5.H1571
Semis, M., Gugiu, G. B., Bernstein, E. A., Bernstein, K. E., & Kalkum, M. (2019). The plethora of angiotensin-converting enzyme-processed peptides in mouse plasma. Analytical Chemistry, 91, 6440-6453. https://doi.org/10.1021/acs.analchem.8b03828
Stewart, J. M. (2004). Bradykinin antagonists: Discovery and development. Peptides, 25, 527-532. https://doi.org/10.1016/j.peptides.2003.10.016
Suzuki, K., Abiko, T., & Endo, N. (1969). Synthesis of every kinds of peptide fragments of bradykinin. Chemical & Pharmaceutical Bulletin, 17, 1671-1678. https://doi.org/10.1248/cpb.17.1671
Uhlen, M., Zhang, C., Lee, S., Sjostedt, E., Fagerberg, L., Bidkhori, G., Benfeitas, R., Arif, M., Liu, Z., Edfors, F., & Sanli, K. (2017). A pathology atlas of the human cancer transcriptome. Science, 357, eaan2507. https://doi.org/10.1126/science.aan2507
van de Veerdonk, F. L., Netea, M. G., van Deuren, M., van der Meer, J. W., de Mast, Q., Bruggemann, R. J., & van der Hoeven, H. (2020). Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. eLife, 9, e57555.
Verano-Braga, T., Martins, A. L. V., Motta-Santos, D., Campagnole-Santos, M. J., & Santos, R. A. S. (2020). ACE2 in the renin-angiotensin system. Clinical Science, 134, 3063-3078. https://doi.org/10.1042/CS20200478
Wick, M. J., Harral, J. W., Loomis, Z. L., & Dempsey, E. C. (2018). An optimized Evans blue protocol to assess vascular leak in the mouse. Journal of Visualized Experiments: JoVE, 139, 57037. https://doi.org/10.3791/57037
Yang, H. Y., Erdos, E. G., & Levin, Y. (1970). A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochimica et Biophysica Acta, 214, 374-376. https://doi.org/10.1016/0005-2795(70)90017-6